These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23912600)

  • 1. DNA vaccines: a simple DNA sensing matter?
    Coban C; Kobiyama K; Jounai N; Tozuka M; Ishii KJ
    Hum Vaccin Immunother; 2013 Oct; 9(10):2216-21. PubMed ID: 23912600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel strategies to improve DNA vaccine immunogenicity.
    Coban C; Kobiyama K; Aoshi T; Takeshita F; Horii T; Akira S; Ishii KJ
    Curr Gene Ther; 2011 Dec; 11(6):479-84. PubMed ID: 22023477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
    Ishii KJ; Kawagoe T; Koyama S; Matsui K; Kumar H; Kawai T; Uematsu S; Takeuchi O; Takeshita F; Coban C; Akira S
    Nature; 2008 Feb; 451(7179):725-9. PubMed ID: 18256672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune sensing of DNA and strategies for fish DNA vaccine development.
    Chang CJ
    Fish Shellfish Immunol; 2020 Jun; 101():252-260. PubMed ID: 32247047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.
    Lladser A; Mougiakakos D; Tufvesson H; Ligtenberg MA; Quest AF; Kiessling R; Ljungberg K
    Mol Ther; 2011 Mar; 19(3):594-601. PubMed ID: 21157438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and cellular mechanisms of DNA vaccines.
    Coban C; Koyama S; Takeshita F; Akira S; Ishii KJ
    Hum Vaccin; 2008; 4(6):453-6. PubMed ID: 18535407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination.
    Kobiyama K; Jounai N; Aoshi T; Tozuka M; Takeshita F; Coban C; Ishii KJ
    Vaccines (Basel); 2013 Jul; 1(3):278-92. PubMed ID: 26344113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8
    Kanuma T; Yamamoto T; Kobiyama K; Moriishi E; Masuta Y; Kusakabe T; Ozasa K; Kuroda E; Jounai N; Ishii KJ
    J Immunol; 2017 Jun; 198(12):4707-4715. PubMed ID: 28507029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing DNA-induced immune responses for improving cancer vaccines.
    Herrada AA; Rojas-Colonelli N; González-Figueroa P; Roco J; Oyarce C; Ligtenberg MA; Lladser A
    Hum Vaccin Immunother; 2012 Nov; 8(11):1682-93. PubMed ID: 23111166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cytosolic Nucleic Acid-Sensing Pathways for Cancer Immunotherapies.
    Iurescia S; Fioretti D; Rinaldi M
    Front Immunol; 2018; 9():711. PubMed ID: 29686682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.
    Garrod T; Grubor-Bauk B; Yu S; Gargett T; Gowans EJ
    Hum Vaccin Immunother; 2014; 10(9):2679-83. PubMed ID: 25483501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alarmin IL-33 elicits potent TB-specific cell-mediated responses.
    Villarreal DO; Siefert RJ; Weiner DB
    Hum Vaccin Immunother; 2015; 11(8):1954-60. PubMed ID: 26091147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines.
    Suschak JJ; Wang S; Fitzgerald KA; Lu S
    J Immunol; 2016 Jan; 196(1):310-6. PubMed ID: 26590319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses.
    Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P
    Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Adjuvants for DNA Vaccines: Application, Design, Preparation, and Formulation.
    Sabbaghi A; Ghaemi A
    Methods Mol Biol; 2021; 2197():87-112. PubMed ID: 32827133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.
    Leitner WW; Bergmann-Leitner ES; Hwang LN; Restifo NP
    Vaccine; 2006 Jun; 24(24):5110-8. PubMed ID: 16725231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.
    Colluru VT; McNeel DG
    Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells.
    Muthumani G; Laddy DJ; Sundaram SG; Fagone P; Shedlock DJ; Kannan S; Wu L; Chung CW; Lankaraman KM; Burns J; Muthumani K; Weiner DB
    Immunology; 2009 Sep; 128(1 Suppl):e612-20. PubMed ID: 19740322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating APOBEC expression enhances DNA vaccine immunogenicity.
    Almeida RR; Raposo RA; Coirada FC; da Silva JR; de Souza Ferreira LC; Kalil J; Nixon DF; Cunha-Neto E
    Immunol Cell Biol; 2015 Nov; 93(10):868-76. PubMed ID: 25953029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNA.
    Rastogi I; McNeel DG
    Oncoimmunology; 2023; 12(1):2212550. PubMed ID: 37205983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.